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and Yegor S Vassetzky1*Abstract
Background: miRNA profiling performed in myogenic cells and biopsies from skeletal muscles has previously
identified miRNAs involved in myogenesis.
Results: Here, we have performed miRNA transcriptome profiling in human affinity-purified CD56+ myoblasts
induced to differentiate in vitro. In total, we have identified 60 miRNAs differentially expressed during myogenic
differentiation. Many were not known for being differentially expressed during myogenic differentiation. Of these,
14 (miR-23b, miR-28, miR-98, miR-103, miR-107, miR-193a, miR-210, miR-324-5p, miR-324-3p, miR-331, miR-374,
miR-432, miR-502, and miR-660) were upregulated and 6 (miR-31, miR-451, miR-452, miR-565, miR-594 and miR-659)
were downregulated. mRNA transcriptome profiling performed in parallel resulted in identification of 6,616 genes
differentially expressed during myogenic differentiation.
Conclusions: This simultaneous miRNA/mRNA transcriptome profiling allowed us to predict with high accuracy target
genes of myogenesis-related microRNAs and to deduce their functions.
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MicroRNAs (miRNAs) are 20–25 nt-long non-coding
RNAs transcribed predominantly by the RNA polymerase
II [1,2]. miRNAs play an important role in regulating gene
expression at the protein and mRNA levels. They have
been previously shown to inhibit translation initiation and
elongation and induce deadenylation and degradation of
mRNA (for review see [3]). In addition, there are indica-
tions that miRNAs may also activate translation [4].
Along with transcription factors, miRNAs contribute
to skeletal myogenesis (for review see [5]). Myogenic
microRNAs miR-1, miR-133a/b and miR-206 (also
called MyomiRs, as suggested by [6]) regulate myogenic* Correspondence: vassetzky@igr.fr
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reproduction in any medium, provided the ordifferentiation and proliferation of myogenic cells by
targeting important regulators of myogenesis [7,8] (for re-
view see [6,9]). MiR-1 and miR-133a are expressed in both
skeletal and cardiac muscles [7,10], while miR-133b and
miR-206 are expressed solely in skeletal muscles [10].
Most miRNAs expressed in skeletal muscles are found
to be upregulated during myogenesis. These include
miR-24 [11], miR-26a [12], miR-27b [13], miR-29b/c
[14], miR-143 [15], miR-181 [16], miR-208b/499 [17],
miR-214 [18], miR-322/424 and miR-503 [19], miR-486
[20], miR-682 [21]. Only few known miRNAs are in-
volved in the regulation of myogenic differentiation are
downregulated during myogenesis. These include miR-
125b [22] and miR-221/222 [23] (for review see [5,24,25]).
Altogether, myogenesis-related miRNAs have been
studied during myogenic differentiation of human pri-
mary myoblasts [14,15,26,27] and in various modell Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12,16,20,28], murine primary satellite cells and myo-
genic progenitor cells [21] as well as quail myoblasts
[29]. Several myogenesis-related miRNAs have been dis-
covered or confirmed by expression profiling of develop-
ing muscular tissues in humans [30], pigs [31] and in the
common carp [32] (Table 1).
To perform transcriptome profiling of myogenic cells, it
appears interesting to use primary myogenic cells culti-
vated in vitro rather than whole muscle tissues. This ap-
proach minimizes biases caused by the presence of
inflammatory, connective tissue-derived and other non-
myogenic cells. Nevertheless, totally avoiding contamin-
ation by non-myogenic cells is difficult unless clonal
populations of immortalized myogenic cells are used.
An alternative to generating immortalized lines of
myogenic cells is the utilization of primary cell popula-
tion enriched for myogenic precursors. However, in
previous miRNA and mRNA expression profiling re-
ports, primary skeletal myoblasts cultivated in vitro
have not been enriched for myogenic cells prior to
analysis.
In the present study, we have thus decided to profile
miRNA expression in cultures of CD56+ primary myo-
blasts and myotubes isolated from healthy individuals
using an affinity purification procedure [35]. A total of
60 miRNAs were found to be differentially expressed
during myogenic differentiation induced by serum star-
vation of which 20 had not been previously associated
with myogenesis. In addition, we have performed micro-
array mRNA transcriptome profiling on the same myo-
blasts and myotubes samples as used for miRNA
expression profiling in order to assign targets for these
miRNAs.
Results
Identification of new myogenesis-related MIRNA
(MRMIRNA) in human primary myoblasts
To identify new myogenesis-related miRNAs in human
cells, CD56+ myogenic precursors were isolated from
skeletal muscle biopsies of six healthy individuals
(Additional file 1). These were then induced to differ-
entiate in vitro using serum starvation and the pro-
gression of myogenic differentiation was monitored by
following the expression of Myogenin (MYOG) and
other myogenic differentiation markers including ID1,
TNNT1, TNNT2, MYL4, COL15A1, VIM and CAV1
(Figure 1A). The disappearance of proliferating cells
and concomitant emergence of myotubes was moni-
tored using Ki67 staining and microscopic observation
(Figure 1B and C).
We observed a statistically significant difference of the
expression levels of myogenesis-related markers in pro-
liferating or differentiated myogenic cells isolated fromdifferent healthy subjects. This difference was considered
as a natural heterogeneity of gene expression levels in
different subjects that might be explained by their age,
sex, physical activity or diet preferences, therefore, all
samples analyzed were included in the study.
The expression of 365 different microRNAs was then
profiled in human primary myoblasts and myotubes using
TaqMan Low Density Array (TLDA) (Additional file 2). In
total, 60 miRNAs were found to be differentially expressed
during myogenic differentiation with p-values ranging
from 3.4x10-5 to 5x10-2 (Figure 2). These will be referred
to as myogenesis-related miRNAs (MR-miRs). Sequences
and corresponding TaqMan probe codes for these
microRNAs can be found in the Additional file 3.
The majority (43 out of 60) of MR-miRs were found to
be upregulated of which 14 had not been previously
reported as involved in the regulation of myogenesis ei-
ther in humans or in other species (Table 1). Of the 17
MR-miRs that were found to be downregulated during
myogenesis, 6 had not been previously associated with
myogenic differentiation.
MRNA transcriptome profiling and functional
classification of differentially expressed genes
Until now, mRNA expression profiling of human myoblasts
has been performed exclusively on primary cells [36]. How-
ever, primary skeletal myoblasts have not been enriched for
myogenic cells prior to analysis. To avoid analyzing mixed
populations of myoblasts and non-myogenic cells, we have
used RNA extracted from CD56+ myoblasts purified from
muscular tissues. Then, using Agilent transcriptome 44 K
microarrays, we identified 6,616 differentially expressed
genes of which 3,445 and 3,245 were down- or up-regulated,
respectively (Additional file 4). In most cases, a functional
class could be assigned to these transcripts using the DAVID
Gene Ontology database (Additional file 5) [37,38].
In agreement with previous reports, the majority of
upregulated genes were found to control metabolism,
myogenesis, insulin receptor signaling or to positively regu-
late transcription (Table 2). Genes involved in the control of
cell cycle, DNA damage response, angiogenesis, cell motility
and invasion as well as protein modification and NF-kB sig-
naling belonged to the group of genes downregulated during
myogenic differentiation (Table 2). Genes involved in the
regulation of ubiquitination/proteolysis, protein transport/
localization, transcription regulation and apoptosis were
found to be either up- or down-regulated (Table 3). The
complete list of genes found to be differentially expressed
during in vitro myogenic differentiation of human primary
myoblasts can be found in the Additional file 4.
Predication of myogenesis-related MIRNA target genes
A common practice to boost target gene predictions ac-
curacy is to use several prediction algorithms and then
Table 1 microRNAs (MR-miRs) found to be up- and downregulated during myogenic differentiation in this study
microRNA This
study
Human (homo sapiens) Mouse (Mus musculus) Pig Common carp
1 miR-1 ↑↑↑ enriched in sk. muscle[15]
↑pMyo diff. [26] ↑ muscle
development [30]
↑ C2C12 diff [7,8,10,33] ↑ pMyo
diff [33]
↑ muscle
development [31]
↑ muscle
development [32]
2 miR-15a ↑↑ (this study) ↓ pMyo diff [33] ↑ muscle
development [31]
3 miR-16 ↓ (this study) ↓ C2C12 diff [33] ↓ pMyo
diff [33]
↑ muscle
development [31]
4 miR-21 ↑ ↑ pMyo diff. [26] - ↑ muscle
development [32]
5 miR-22 ↑ (this study) ↑ C2C12 diff [33] ↑ pMyo diff [33] ↑ muscle
development [31]
6 miR-23b (n) ↑ (this study)
7 miR-24 ↑ ↑pMyo diff. [26] ↑pMyo diff, ↑ C2C12 diff [11,33] ↑
C2C12 diff [28,33]
enriched in
heart [32]
8 miR-26a ↑ ↑pMyo diff. [26] ↑ C2C12 diff [12,28] ↑ pMyo
diff [33]
↑ muscle
development [32]
9 miR-27a ↑ ↑pMyo diff. [26] ↑ pMyo diff [33] ↑ muscle
development [31]
↓ muscle
development [32]
10 miR-27b ↑ (this study) ↑ pMyo [13,33] ↑ C2C12 diff
[28,33]
11 miR-28 (n) ↑ (this study) -
12 miR-29a ↓ (this study) ↓ C2C12 diff [28] ↑ C2C12
diff [33]
13 miR-30a-5p ↑↑ (this study) ↑ C2C12 diff [28,33]
14 miR-30a-3p ↑ (this study) ↑ C2C12 diff [33]
15 miR-30c ↑ ↑pMyo diff. [26] ↑ C2C12 diff [33] ↑ muscle
development [31]
16 miR-30d ↑↑ (this study) ↑ pMyo diff [33]
17 miR-30e-3p ↑ (this study) ↑ pMyo diff [33]
18 miR-31 (n) ↓ (this study)
19 miR-98 (n) ↑ (this study)
20 miR-99a ↓ (this study) ↑ C2C12 diff [33] ↑ pMyo diff [33]
21 miR-101 ↑↑ (this study) - ↑ muscle
development [31]
22 miR-103 (n) ↑ (this study)
23 miR-107 (n) ↑ (this study) -
24 miR-126 ↑↑ (this study) ↓ C2C12 diff [33]
25 miR-128b ↑↑↑ ↑ pMyo diff. [27] ↑ C2C12 diff [28] ↑ pMyo diff [33]
26 miR-133a ↑↑↑ enriched in sk. muscle[15]↑pMyo
diff. [26] ↑ muscle development [30]
↑ C2C12 diff [8,10,33] ↑ pMyo
diff [33]
↑ muscle
development [31]
↑ muscle
development [32]
27 miR-133b ↑↑↑ enriched in sk. muscle[15] ↑
muscle development [30]
↑ C2C12 diff [8,10] ↑ pMyo
diff [33]
28 miR-140 ↑ (this study) ↑ pMyo diff [33]
29 miR-152 ↑ (this study) ↑ C2C12 diff [28]
30 miR-155 ↓↓ (this study) ↓ C2C12 diff [34,35] ↓ pMyo
diff [33]
31 miR-181b ↑ (this study) ↑ C2C12 diff [16,28,33] ↑ pMyo
diff [33]
enriched in the
heart [32]
32 miR-183 ↓ (this study) ↓ C2C12 diff [33]
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Table 1 microRNAs (MR-miRs) found to be up- and downregulated during myogenic differentiation in this study
(Continued)
33 miR-192 ↑↑ (this study) ↑ pMyo diff [33]
34 miR-193a (n) ↑↑ (this study) -
35 miR-204 ↓↓ ↓ pMyo diff. [27] -
36 miR-206 ↑↑ enriched in sk. muscle[15] ↑
muscle development [30]
↑ C2C12 diff [8,10,33] ↑
pMyo diff [33]
↑ muscle
development
37 miR-210 (n) ↑ (this study)
38 miR-221 ↓ ↑pMyo diff. [26]↓ pMyo diff. [27] ↓quail myoblasts diff, ↓
C2C12 diff [29]
39 miR-222 ↓ ↑pMyo diff. [26] ↓ pMyo diff. [27] ↓quail myoblasts diff, ↓ C2C12
diff [29] ↓ C2C12 diff [28]
↓ muscle
development [32]
40 miR-320 ↓ (this study) ↑ pMyo diff [33]
41 miR-324-3p (n) ↑↑ (this study)
42 miR-324-5p (n) ↑ (this study)
43 miR-331 (n) ↑ (this study) -
44 miR-339 ↓ (this study) ↑ C2C12 diff [33] ↑ pMyo diff [33]
45 miR-361 ↑ (this study) ↑ pMyo diff [33]
46 miR-362 ↑↑ (this study) ↑ C2C12 diff [28]
47 miR-374 (n) ↑ (this study)
48 miR-432 (n) ↑ (this study)
49 miR-451 (n) ↓↓↓ (this study)
50 miR-452 (n) ↓↓ (this study)
51 miR-500 ↑↑ (this study) ↑ C2C12 diff [28,33] ↑ pMyo
diff [33]
52 miR-501 ↑↑↑ (this study) ↑ C2C12 diff [28,33]
53 miR-502 (n) ↑↑ (this study) -
54 miR-503 ↑ (this study) ↑ C2C12 diff [19,28,33] ↑ pMyo
diff [33]
55 miR-532 ↑↑ (this study) ↑ C2C12 diff [28,33] ↑ pMyo
diff [33]
56 miR-550 ↓ ↓ pMyo diff. [27] -
57 miR-565 (n) ↓ (this study) -
58 miR-594 (n) ↓ (this study)
59 miR-659 (n) ↓↓↓ (this study) -
60 miR-660 (n) ↑↑↑ (this study) -
In bold are human-specific MR-miRs (hMR-miRs, 16 in total); Italicized are microRNAs shown to be differentially expressed during myogenesis in non- human cells;
microRNAs with a known function in myogenesis are underscored. (n): microRNAs that we have shown to be differentially expressed during myogenesis for the
first time in our study. The number of arrows corresponds to the level of up- or downregulation of microRNAs. One arrow: fold change 1 to 3 fold, two arrows:
fold change 3 to 7 times, three arrows: fold change 7 to infinity.
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has been proved inefficient [39]. Therefore, we have used
a single algorithm, e.g. RNA22 [40] to predict miRNA
targets. RNA22 has been chosen for its low rate of false-
positive predictions as compared to other algorithms
[39]. For each miRNA, the number of target predictions
varied between 261 and 3,058.
According to previous reports, the proportion of correct
predictions can be as low as 10% [41,42] (for recent review
see [43]. To increase the accuracy of bioinformaticpredictions, we used a simultaneous mRNA/miRNA expres-
sion profiling approach described in [42,44,45]. Based on the
fact that MiRNA regulate gene expression by inhibiting
translation or inducing deadenylation of mRNAs followed
by their degradation (for review see [46,47]), we reasoned
that the expression levels of mRNA and miRNA should be
inversely correlated if one regulates the other. Indeed, for
upregulated MR-miRNA, the majority of their predicted tar-
get genes was found to be underexpressed. Similarly, most
downregulated MR-miRNAs had upregulated predicted
Figure 1 (See legend on next page.)
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Figure 1 Expression of myogenic differentiation markers and miRNA profiling. A. Expression of muscle differentiation markers MYOG (myogenin,
myogenic factor 4, p-value=0.0016), TNNT1 (Troponin T type 1, skeletal slow, p-value=0.00064), MYL4 (myosine light chain 4, p-value=0.0016),
COL15A1 (collagen, type XV, alpha 1, p-value=0.013), TNNT2 (troponin T type 2 (cardiac), p-value=4.8x10^-6), VIM (vimentin, p-value=0.00034), ID1
(inhibitor of DNA binding 1, p-value=1.9x10^-5) and CAV1 (caveolin 1, p-value=0.00015) in proliferating myoblasts (labeled as P) and
differentiated myotubes (labeled as D) was measured using qRT-PCR, normalization was performed using ΔΔCt method using GAPDH as a
control gene and proliferating sample #1 as a reference sample (expression level 1). The average of three independent experiments is shown.
Numbers from 1 to 6 indicate the sample number (for full description refer to Table S1). Insets indicate the average of 6 samples of proliferating
myoblasts (P) and differentiated myotubes (D). Asterisk corresponds to p-values<0.05. Error bars correspond to standard deviation (SD) in the case
of individual samples and standard error of the mean (SEM) in the case of average expression levels (inset). B. Results of immunofluorescence
microscopy analysis of cells stained with anti-Ki67 (red), and anti-Desmin (green) antibodies and DAPI nuclear staining (blue) showing normal
cellular localization of these proteins in proliferating myoblasts and differentiated myotubes, 20x magnification. Bar=10 μm. C. The number of
Ki67+ cells is significantly reduced during myogenic differentiation in vitro. Results of quantification of the DES+ and Ki67+ cells representing 300
individual cells. Statistically significant difference between cell cultures of proliferating myoblasts and differentiated myotubes is indicated by an
asterisk (t-test p-value<0.05).
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of Pearson correlation coefficients of its predicted target
genes was shifted towards negative values. This was the case
neither for randomly selected genes, nor when the sample
correspondence was permuted (Figure 3A and the
Additional file 6) which was used to establish a signifi-
cance threshold of Pearson correlation coefficients.
Target genes with correlation coefficients below the
threshold had less than 5% chances to be random. We
call these genes “supported targets” to underscore the
fact that the prediction was supported by mRNA tran-
scriptome profiling (Additional file 7). On average,
11% of microRNA target genes predicted by the
RNA22 algorithm were “supported” by mRNA tran-
scriptome profiling (Figure 3B).
We then compared the accuracy of predictions made
by RNA22 and TargetScan, another popular miRNA tar-
get prediction algorithm. As an indication of accuracy,
we have used a percentage of predicted targets that were
supported by transcriptome data. For 11 of 17 target
genes, RNA22 demonstrated higher percentage of pre-
dictions supported by transcriptome data, for 2 more
microRNAs the difference in the accuracy of predictions
was insignificant (Figure 3C and Additional file 8).
QRT-PCR validation of supported MIRNA target genes
To demonstrate the relevance of our miRNA target pre-
dictions, we altered the expression of several microRNAs
and measured the expression of their predicted target
genes, supported by the transcriptome data. To illustrate
the impact of miRNA repression on the expression of
their target genes, we have chosen to inhibit the expres-
sion of four well-characterized myogenic microRNAs
miR-1, -133a, -133b and −206 in human immortalized
myoblasts using LNA (Locked Nucleic Acids) antisense
microRNAs (anti-miRs). Human immortalized myoblasts
were differentiated in vitro and then transfected separ-
ately with anti-miRs targeting miR-1, miR-133a, miR-
133b and miR-206. miR-1 and miR-206 have the sameseed sequence and, therefore, target very similar lists of
genes. The same is true for miR-133a and miR-133b. We
have then randomly selected 12 and 10 genes predicted
to be targeted by miR-1/206 and miR-133a/b respect-
ively and supported by our transcriptome data and
tested their expression using qRT-PCR in the cells
transfected with corresponding anti-miRs. Repressing
miR-1/206 resulted in the upregulation of six of its tar-
gets: AP3D1 (adaptor-related proteins complex 3, delta 1
subunit), COL3A1 (collagen, type III, alpha 1), HDAC1
(histone deacetylase 1), PDCD4 (programmed cell death 4),
PRKAB2 (protein kinase, AMP-activated beta 2 non-
catalytic subunit) and ZNF365 (zinc finger protein 365).
These target genes were considered as novel “qRT-PCR val-
idated” target genes of miR-1 and −206 (Figures 4A). Six
other target genes supported by our transcriptome data in-
cluding ATP2B1, C11orf45, FOXP, G2E3, MBOAT7 and
TUBB could not be validated via qRT-PCR experimentally,
as we did not observe significant changes of their expres-
sion following anti-miR transfection (data not shown).
In the case of miR-133a and -133b, immortalized myotube
transfection anti-miRs resulted in the upregulation of six of
ten randomly selected target genes, supported by our tran-
scriptome data. These novel qRT-PCR validated targets of
miR-133a and -133b include ASAP2 (ArfGAP with SH3 do-
main, ankyrin repeat and PH domain 2), ARFGAP1 (ADP-
ribosylation factor GTPase activating protein 1), ATP1A2
(ATPase, Na+/K+ transporting, alpha 2 polypeptide),
C7orf51 (chromosome 7 open reading frame 51), RBM15B
(RNA binding motif protein 15B) and TMCC2 (transmem-
brane and coiled-coil domain family 2) (Figures 4B). Four
other target genes supported by our transcriptome data in-
cluding LMCD1, NAT9, PRPF38A and SYNGR2 could not
be validated via qRT-PCR, as we did not observed significant
changes of their expression following anti-miR transfection
(data not shown).
To illustrate the impact of miRNA overexpression on
the expression of their target genes, we have selected
two microRNAs, miR-30 and −128, that were previously
#microRNA 1P 2P 3P 4P 5P 6P 1D2D 3D 4D 5D 6D Fold upreg.
1 hsa-miR-1 38.70
2 hsa-miR-15a 3.29
3 hsa-miR-21 2.15
4 hsa-miR-22 2.18
5 hsa-miR-23b 2.18
6 hsa-miR-24 1.68
7 hsa-miR-26a 2.26
8 hsa-miR-27a 2.37
9 hsa-miR-27b 1.78
10 hsa-miR-28 1.50
11 hsa-miR-30a-5p 3.61
12 hsa-miR-30a-3p 1.97
13 hsa-miR-30c 2.07
14 hsa-miR-30d 3.65
15 hsa-miR-30e-3p 2.17
16 hsa-miR-98 2.20
17 hsa-miR-101 4.01
18 hsa-miR-103 1.52
19 hsa-miR-107 2.08
20 hsa-miR-126 3.19
21 hsa-miR-128b
22 hsa-miR-133b 16.67
23 hsa-miR-133a 31.22
24 hsa-miR-140 1.66
25 hsa-miR-152 1.71
26 hsa-miR-181b 1.35
27 hsa-miR-192 4.70
28 hsa-miR-193a 3.34
29 hsa-miR-206 6.88
30 hsa-miR-210 1.85
31 hsa-miR-324-5p 3.01
32 hsa-miR-324-3p 1.83
33 hsa-miR-331 2.27
34 hsa-miR-361 2.86
35 hsa-miR-362 6.52
36 hsa-miR-374 1.87
37 hsa-miR-432 2.25
38 hsa-miR-500 3.52
39 hsa-miR-501 8.59
40 hsa-miR-502 3.43
41 hsa-miR-503 1.65
42 hsa-miR-532 6.81
43 hsa-miR-660 11.44
44 hsa-miR-16 -1.30
45 hsa-miR-29a -1.66
46 hsa-miR-31 -2.23
47 hsa-miR-99a -1.45
48 hsa-miR-155 -3.20
49 hsa-miR-183 -2.44
50 hsa-miR-204 -3.86
51 hsa-miR-221 -1.57
52 hsa-miR-222 -2.41
53 hsa-miR-320 -1.45
54 hsa-miR-339 -2.94
55 hsa-miR-451
56 hsa-miR-452 -4.20
57 hsa-miR-550 -2.48
58 hsa-miR-594 -1.48
59 hsa-miR-565 -2.72
60 hsa-miR-659 -7.33
1    2  4  6   8  10
microRNA expression. fold upregulation
Figure 2 miRNA profiling in proliferating myoblasts (left) and
differentiated myotubes (right). Out of 365 miRNAs tested, this
table shows 60 miRNAs that were differentially expressed in
myotubes as compared to myoblasts. Gray levels indicates the
expression level of microRNA in each individual sample tested.
Labels 1P to 6P correspond to samples of proliferating myoblasts
described in Table S1, labels 1D to 6D correspond to the samples of
differentiated myotubes described in Additional file 1: Table S1.
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[26,27], but their function in myogenesis is not well-
established. Two plasmids coding for the corresponding
pre-miRNAs or scrambled sequence were transfected
separately into human rhabdomyosarcoma cells, and the
expression of their target genes was then tested via qRT-
PCR. Ectopic overexpression of miR-128 led to the
downregulation of three of its four target genes, randomly
selected among the genes supported by our transcriptome
data. These novel qRT-PCR validated miR-128 target genes
include EDARADD (EDAR-associated death domain),
CAV1 (Caveolin 1) and DTYMK (deoxythymidylate kin-
ase) (Figures 4C). One transcriptome-supported miR-128
target gene, RBM15B, could not be validated using qRT-
PCR, as we did not observed significant changes in its ex-
pression level following miRNA precursor tranfection (data
not shown).
Similarly, overexpressing miR-30 led to the downregulation
of three of its five randomly selected transcriptome-
supported targets. These qRT-PCR validated miR-30 tar-
gets include PLXNB (plexin B2), C11orf45 (chromosome
11 open reading frame 45) and ATP2B1 (ATPase, Ca++
transporting, plasma membrane 1) (Figures 4D). Two
remaining miR-30 target genes, PPIA and CASD1 could
not be validated via qRT-PCR, as we did not observed sig-
nificant changes in its expression level following miRNA
precursor transfection (data not shown).
Overall, at least 50% of the supported target genes
tested in this study appeared to be regulated by their
corresponding microRNA either directly or indirectly
which is significantly better than the result of ordinary
bioinformatic prediction with only 10% of correctly pre-
dicted target genes.
Functional analysis of MR-MIRNA target genes supported
by transcrptome data
After functional classification of genes differentially
expressed during myogenic differentiation in vitro, we
thought to determine the proportion of microRNA-
controlled genes within each functional class. Almost
30% of all protein coding genes contain miRNA seeds in
their 30UTRs and are, therefore, potential miRNA tar-
gets [48]. Indeed, we have found that a significant propor-
tion of genes differentially expressed during myogenic
Table 2 Specific functional classes of genes differentially expressed during myogenic differentiation
Specific functional classes Unique genes/cluster % targets P-value FDR Cluster code
Upregulated
1 Myogenesis
- muscle contraction 81 8,64 3,881E-19 7,23E-16 1_up
- muscle development 145 13,79 6,37E-09 1,19E-05 2_up
- embryonic development 85 11,76 0,0001374 0,255618 3_up
2 Metabolism
- cellular respiration 179 12,85 2,21E-24 4,12E-21 4_up
- phosphate metabolism 217 13,82 2,459E-16 4,11E-13 5_up
- cofactor biosynthesis 57 12,28 5,177E-09 9,64E-06 6_up
- carbohydrate metabolism 50 18,00 1,556E-06 0,002898 7_up
3 Signaling
- insulin receptor signaling 132 19,70 2,61E-07 0,000486 8_up
4 Transcription
- transcription (+) reg 220 15,00 2,624E-07 0,000489 9_up
Downregulated
1 cell cycle
- cell cycle regulation 285 35,09 1,04E-51 1,95E-48 1_down
- chromosome segregation 42 26,19 2,51E-15 4,77E-12 2_down
- M-phase 31 32,26 3,75E-07 0,000702 3_down
- interphase 34 20,59 2,9E-08 5,43E-05 4_down
- DNA replication 38 34,21 8,04E-06 0,015052 5_down
- centrosome cycle 19 15,79 1,6E-06 0,002987 6_down
2 DNA damage response
- DNA damage response 253 39,53 2,8E-38 5,23E-35 7_down
- telomere maintenance 24 29,17 3,02E-05 0,056435 8_down
3 Wound healing/angiogensis
- wound healing 58 44,83 5,52E-08 0,000103 9_down
- angiogenesis 54 55,56 1,14E-05 0,021416 10_down
4 Cell motility/migration
- cell motility 87 44,83 1,72E-05 0,032183 11_down
5 Protein modification/assembly
- protein glycosylation 36 36,11 0,001102 2,041321 12_down
- protein modification 88 46,59 4,82E-05 0,090071 13_down
6 Metabolism
- nucleotide biosynthesis 84 41,67 5,39E-07 0,001009 14_down
7 Signaling
- response to calcium 40 40,00 2,91E-05 0,054402 15_down
- NF-kB 65 50,77 0,003016 5,494941 16_down
- phosphorylation 163 38,65 3E-07 0,000561 17_down
8 Transcription
- RNA splicing 135 36,30 3,48E-17 6,51E-14 18_down
Subclasses are italicized, the cutoff value for differentially expressed genes was set to 1.2 fold change.
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Table 3 Common functional classes unifying genes up- and downregulated during myogenic differentiation
Common functional classes Unique genes/cluster UP/DOWN % miRNA targets P-value FDR
1 Protein modification/assembly
ubiquitination/proteolysis 305 UP 16,07 4,118E-23 7,67E-20 10_up
162 DOWN 39,51 2,97E-05 0,055652 19_down
protein complex assembly 131 UP 9,16 0,0001135 0,21125 11_up
177 DOWN 30,51 7,01E-17 2,11E-13 20_down
2 Transport/localization
transport/localization 243 UP 16,05 1,299E-17 2,42E-14 12_up
279 DOWN 41,22 1,27E-11 2,39E-08 21_down
3 Transcription
transcription regulation 458 UP 13,32 7,64E-10 1,42E-06 13_up
36 DOWN 41,67 0,000311 0,57965 22_down
transcription (−) reg, 148 UP 11,49 9,994E-07 0,001862 14_up
203 DOWN 36,45 1,19E-09 2,23E-06 23_down
chromatin organization/modification 86 UP 9,30 0,0005777 1,070598 15_up
153 DOWN 30,72 5,88E-23 1,1E-19 24_down
4 Apoptosis
apoptosis 216 UP 17,59 8,615E-07 0,001605 16_up
216 DOWN 38,43 1,26E-08 2,36E-05 25_down
5 Signaling
reg, of kinase activity 204 UP 15,69 1,362E-06 0,002537 17_up
233 DOWN 40,77 2,22E-06 0,00416 26_down
6 Cell morphogenesis
cytoskeleton organization 130 UP 14,62 0,0002361 0,438978 18, 19_up
193 DOWN 35,23 1,05E-17 1,96E-14 27_down
Subclasses are italicized, the cutoff value for differentially expressed genes was set to 1.2 fold change.
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However, the proportion of genes targeted by microRNAs
was not the same within different functional classes. For
example, 50% to 55% of genes related to angiogenesis and
NF-kB signaling were potentially targeted by miRNAs,
while in the case of myogenesis, potential miRNA targets
represented only 8.6% of genes (Table 2). Interestingly,
more miRNA targets were found among downregulated
than upregulated genes. For example, among apoptosis-
related genes, 17.6% of upregulated and 38.4% of
downregulated genes were found to be targeted by
miRNAs (Table 3). This observation prompted us to
search for known functions of each supported target gene
of every MR-miRNA described in this study using DAVID
functional annotation tool [37,38].
miR-1 and miR-206
It has been previously demonstrated that miR-1 and −206
target genes linked to the regulation of chromatin modifi-
cations [8], transcription [20,49] and cell cycle [50]. Func-
tional analysis of predicted miR-1 target genes supportedby transcriptome data indicated that these microRNAs
might also target genes involved in the regulation of apop-
tosis, DNA damage response, cell motility and protein
modification, cell signaling and kinase activity [33]. Our
own functional analysis of predicted target genes of miR-1
and −206 supported by transcriptome analysis confirmed
that miR-1 and miR-206 might target genes involved in in
these biological processes. In addition, miRNA-1 and −206
might target genes implicated in cytoskeleton organization,
ubiquitination and nucleotide biosynthesis (Figure 5,
Additional file 9).
miR-21
It has been demonstrated that miR-21 targets genes in-
volved in in apoptosis [51,52] and regulation of kinase ac-
tivity [53-56] and regulation of gene expression [57]. Here
we confirm that miR-21 might target genes involved in
these biological processes and might also target genes in-
volved in transport, cell cycle regulation, chromatin assem-
bly, protein modification, NF-kB signaling, protein complex
assembly and DNA damage (Figure 5, Additional file 9).
Figure 3 (See legend on next page.)
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Figure 3 Bioinformatic predictions of microRNA target genes. A. Density plot of Pearson correlation coefficients between expression of
miRNA and their target genes (continuous line) predicted by RNA22 algorithm. Number of genes is expressed as% of total predictions indicated
within each plot. The distribution of Pearson correlations is clearly shifted towards negative values; the density plot of Pearson correlation
coefficient after permutation of the list of microRNAs (dashed line). In this case the distribution is centered around zero. Several examples are
shown, for other microRNAs see the Additional file 6. B. Diagram showing the proportion of bioinformatic predictions made by RNA22 algorithm
(taken for 100%) that were supported by transcriptome profiling (black). Light grey shows unsupported predictions. The graphs corresponding to
TargetScan predictions are presented in the Additional file 8. C. Comparison of the accuracy of target gene predictions by RNA22 and TargetScan
algorithms.% of target genes predicted by both algorithms and supported by transcriptome data is shown.
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It has been demonstrated that miR-24 is involved in DNA
damage response [58,59], regulation of cell cycle progres-
sion [59,60], regulation of kinase activity and protein
phosphorylation [61], transcription [62] and apoptosis
[63]. We confirm that miR-24 might control genes impli-
cated in these biological processes. In addition, miR-24
might control genes implicated in the regulation of trans-
port , NF-kB signaling, protein ubiquitination and com-
plex assembly, RNA splicing and chromatin modification
(Figure 5, Additional file 9).
miR-26a
It has been previously demonstrated that miR-26a target
genes are implicated in cell cycle control [64], apoptosis
[65], regulation of kinase activity and protein phosphor-
ylation [66], as well as chromatin modification [12]. Here
we confirm that miR-26a might target genes involved in
the regulation of cell cycle, apoptosis, kinase activity and
protein phosphorylation, but not in chromatin modifica-
tion. In addition, miR-26a might target genes involved in
the regulation of transport, DNA damage response, pro-
tein modification and protein complex assembly, as well
as nucleotide biosynthesis and RNA splicing (Figure 5,
Additional file 9).
miR-27a
miR-27b is involved in the regulation of transcription by
inhibiting the expression of various transcription factors
[13,67-70]. Here we confirm the role of miR-27b as an im-
portant transcriptional regulator, in addition, our predic-
tions suggest that miR-27a might be involved in the
regulation of intracellular transport, apoptosis, kinase ac-
tivity, protein complex assembly, cytoskeleton organization
and other biological functions including DNA damage re-
sponse, cell cycle, motility, nucleotide biosynthesis and
protein phosphorylation (Figure 5, Additional file 9).
miR-30c
miR-30 was shown to induce apoptosis [71] and regulate
cell motility by influencing extracellular the matrix re-
modelling process [72-74]. This microRNA is also known
to regulate protein modification e.g. sumoylation [75] and
transcription [72,73,76,77]. We here confirm that miR-30cmight target genes participate in the regulation of apop-
tosis and cell motility regulation but not transcription
control. Instead, our predictions suggest that miR-30
might target genes involved in the regulation of protein
phosphorylation and kinase activity, cell cycle control,
intracellular transport, cytoskeleton organization, protein
ubiquitination, DNA damage response and nucleotide bio-
synthesis (Figure 5, Additional file 9).
miR-128b
It has been previously demonstrated that miR-128b tar-
gets genes involved in the regulation of cell cycle [78,79],
transcription [78,79] and apoptosis [79,80]. In addition,
transcriptome analysis of cell transfected with miR-128 re-
vealed an alteration of the expression of genes implicated
in cytoskeleton organization, kinase activity and protein
phosphorylation [81]. Here we confirm the target genes of
miR-128 might be involved in these biological functions.
In addition, our predictions suggest that miR-128 might
target genes in DNA damage response, transport, protein
modification and ubiquitination and cell motility (Figure 5,
Additional file 9).
miR-133a and miR-133b
Previously, these microRNAs have been shown to control
genes involved in the regulation of transcription [8,82],
cytoskeleton structure [83-87], apoptosis [88] and mRNA
splicing [89]. Here we confirm that miR-133a/b might tar-
get genes involved in these biological functions. In addition,
miR-133a/b might target genes involved in intracellular
transport, cell cycle regulation, DNA damage response,
protein phosphorylation and ubiquitination (Figure 5,
Additional file 9).
miR-204
It has been previously shown that miR-204 is involved in
the regulation of transcription [90-92], controls cell migra-
tion cytoskeleton organization [92-94]. miR-204 has been
also shown to be involved in regulation of apoptosis by
targeting multiple genes [95] and in the regulation of cell
signaling [94, 96]. Here we confirm that miR-204 might
target genes involved in transcription regulation, cytoskel-
eton organization and apoptosis but not cell signaling and
cell migration. Furthermore, our predictions suggest that
Figure 4 (See legend on next page.)
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Figure 4 Confirmation of bioinformatic predictions of miR targets. Human immortalized myoblasts (iMyo) cultivated in growth medium (P)
or differentiation medium for 3 days (D) were transfected with either control LNA (anti-miR-C) or LNA against miR-1 and miR-206, miR-133a and
miR-133b (A). Human rhabdomyosarcoma cells (RD) were transfected with plasmids coding for miR-128 and miR-30 precursors or scrambled
sequence (scr) (B). Then the expression of corresponding microRNA and their randomly selected target genes was tested using qRT-PCR,
normalization was performed using ΔΔCt method using GAPDH as a control gene and proliferating sample #1 as a reference sample (expression
level 1). Transcriptome-supported target genes of miR-1/206 (C) and miR-133a/b (D) were downregulated during normal myogenic differentiation
but not when it was accompanied by the transfection with corresponding anti-miRs. Transcriptome-supported target genes of miR-128 and
miR-30 were downregulated when human rhabdomyosarcoma cells were transfected with lentiviral constructs overexpressing miR-128 (E) and
miR-30 (F). The average of three independent experiments is shown. (*) indicates p-value <0.05; (G): Diagram showing the proportion of
supported predictions that were qRT-PCR validated in this study. Black: validated targets, gray: non-validated targets.
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of ubiquitination, cellular respiration and intracellular
transport (Figure 5, Additional file 9).
miR-221 and miR-222
Previously, these microRNAs have been show to target
genes involved in the process of protein degradation
[97], apoptosis [98], kinase activity [99,100], cell cycle
progression [29] and cell motility [101]. We here con-
firm that miR-221 and −222 might target genes involved
in protein degradation (via ubiquitination), apoptosis,
and kinase activity regulation, but not cell cycle progres-
sion or cell motility. In addition, miR-221 and −222
might also target genes that play a role in the regulation
of transcription, insulin signaling, intracellular transport
and cellular respiration (Figure 5, Additional file 9).
miR-550
No target genes and functions of this microRNA were
not previously described. Our predictions suggest that
miR-550 might target genes involved in the regulation of
transcription, protein ubiquitination, phosphate metab-
olism, apoptosis, insulin signaling, muscle development,
intracellular transport and cellular morphology (Figure 5,
Additional file 9).
The full list of supported target genes of MR-miRs
with and without assigned functions can be found in the
Additional file 7.
Discussion and conclusion
MicroRNAs, particularly miR-1, -206 and -133a/b, play
crucial roles in myogenesis [6]. These are called
MyomiRs to underscore their importance in myogenesis
(for review see [24]). Previously, high-throughput profil-
ing of miRNA expression performed in human myo-
blasts have resulted in identification of miRNAs
differentially expressed during myogenic differentiation
[26,27]. Besides that, a larger number of miRNAs have
been found to be differentially expressed during myo-
genic differentiation of mouse C2C12 myoblasts [19,28],
mouse myogenic progenitors [18,21] or at various stages
of development of skeletal muscles in pig [31] or in the
common carp [32].Here, we have compared miRNA expression profiles in
human proliferating primary CD56+ myoblasts and differen-
tiated myotubes. Sixty differentially expressed miRNAs were
identified (MR-miRs). Twenty of these had not been previ-
ously implicated in myogenesis. Conversely, several miRNAs
previously reported as related to myogenic differentiation
were not identified in the present study. These included
miR-214 [18], hsa-miR-424 (identical to mmu-miR-322)
[19], miR-29b/c [14], miR-143, miR-208a [15], miR-208b,
miR-499 [17], miR-125b [102] (Additional file 10). One
miRNA, miR-682, previously shown to be upregulated in
mouse myogenic precursors [21] could not be tested here.
The difficulties to confirm previously reported data for sev-
eral miRNAs associated with myogenesis in model organ-
isms could be due to species-specific characteristics in the
myogenesis program or could originate from differences in
experimental conditions. Indeed, high-throughput miRNA
expression profiling has been previously performed using
mixed cell populations isolated from skeletal myoblasts
[26,27]. The resulting presence of non-myogenic cells, in-
cluding fibroblasts and inflammatory cells, could have al-
tered the resulting miRNA expression profiles. It thus
appears that the existing repertoire of myogenic miRNAs is
still incomplete or contaminated with miRNAs unrelated to
myogenesis. For example, we have demonstrated that miR-
221 and miR-222 were downregulated during myogenic dif-
ferentiation of human myoblasts while others reported their
upregulation [26]. Our results are in agreement with previ-
ous reports demonstrating that these microRNAs are
downregulated during myogenesis in mice [28,29].
In addition to microRNA expression profiling, we have
profiled mRNA expression in myogenic cells in the
course of myogenic differentiation. Transcriptome ana-
lysis of myogenesis has been previously reported by
others. In mice, several models have been used for tran-
scriptome profiling. These include C2C12 immortalized
cell line considered as the “golden standard” of in vitro
myogenic differentiation [103-107], primary mouse myo-
blasts [108] and an in vivo model of muscle regeneration
following injury [109]. In humans, the only published
mRNA expression profiling has been performed on pri-
mary cells grown in vitro [36]. The transcriptome profil-
ing of human myoblasts in the course of myogenic
Figure 5 Predicted functions of MR-miRs. Green: functions downregulated during myogenic differentiation, Red: functions upregulated during
myogenic differentiation. Yellow: functions that are both up- and downregulated during myogenic differentiation. Framed are the functions that
have not been previously ascribed to a given microRNA.
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http://www.biomedcentral.com/1471-2164/14/265differentiation in vitro described here, has two important
advantages over the previously published study. Firstly,
we used CD56+ myogenic cells that allowed us to ex-
clude from the analysis genes unrelated to myogenesis.
Secondly, our study is the first example of a simultan-
eous miRNA/mRNA expression profiling of myogenic
cells.
Simultaneous miRNA/mRNA was used here to identify
novel target genes of myogenesis-related microRNAs. This
approach has been proven efficient for increasing the pre-
cision of bioinformatics predictions for miRNA targets
[42], and it has been applied previously to identify miRNA
target genes in neural tissue [45] and cancer cell lines
[44,110], but not in myogenic cells or muscle tissue.
Several methods are used to validate the target genes
of miRNA. These include qRT-PCR, luciferase assays
and western blot (for review see [111] and [112]). Lucif-
erase assay based on a reporter plasmid containing
miRNA recognition sites in the 30 UTR of the luciferase
gene is the method used to demonstrate the direct in-
hibition of mRNA expression by miRNA. However this
method does not provide information as to whether the
miRNA-dependent regulation occurs at the level of tran-
script stability or at the level of translation, nor the dir-
ect miRNA:mRNA interaction demonstrated by this
method does guarantee the physiological significance of
the observed miRNA effect. Here, to validate the pre-
dicted target genes, we have used qRT-PCR validation
approach. This method is more physiological than lucif-
erase assay as it measures the expression of target gene
from their natural genomic context, although it can not
discriminate between direct and indirect effects of
miRNA expression. Hereby, we have randomly selected
32 genes targeted by 6 different microRNAs including
miR-1, -206, -133a, -133b, -128 and −30 and tested their
expression using pRT-PCR in the cells where corre-
sponding microRNA was ectopically overexpressed or
inhibited. We have demonstrated the miRNA-dependent
inhibition for 18 of these target genes. We called these
genes “qRT-PCR validated” to formally distinguish them
from simply “validated”, as the latter term is usually re-
served for miRNA target genes validated using luciferase
reporters.
On average, we estimate that the lists of predicted tar-
get genes supported by transcriptome data contain at
least 50% of genes that will change their expression,
according to our predictions, in response to the alter-
ations of microRNA expression.
Using the lists of target genes supported by transcrip-
tome data we have deduced functional impact of MR-
miRs using DAVID functional annotation tool [37,38].
Our predictions generally corresponded to already
known functions of MR-miRs demonstrated by others,
but also allowed us to make suggestions about novelfunctions of MR-miRs. It has to be noted, that these pre-
dictions have to be handled with caution for two reasons:
(i) according to our estimation, among target genes sup-
ported by transcriptome analysis, up to 50% might not
react to miRNA alteration, as predicted; (ii) the functions
of MR-miR have been deduced using bioinformatic pre-
diction algorithms that can not substitute for a true ex-
perimental validation of microRNA functions.
To summarize, we have discovered 20 human miRNAs
not previously known to be differentially expressed during
myogenic differentiation and confirmed 40 myogenesis-
related microRNAs. We then used an approach that in-
cluded a simultaneous miRNA/mRNA expression profiling
to predict targets genes of these microRNAs with more
than 50% accuracy, although whether these are direct or
indirect targets of miRNA remains unknown. Finally, we
deduced novel functions of these microRNA from the
known functions of their target genes. Further studies are
necessary to confirm our predictions of functional contri-
bution of newly discovered miRNAs to the process of myo-
genic differentiation.
Methods
Cell culture conditions and transfection
Primary human myoblasts were isolated from skeletal
muscles of healthy subjects as described in [35], for de-
tails see Additional file 4: Table S4), purified with an
immuno-magnetic sorting system (Miltenyi Biotec, USA)
using an anti-CD56/NCAM antibody according to the
manufacturer’s instructions. CD56-positive myoblasts
were seeded in collagen-coated Petri dishes (P1) and cul-
tured in DMEM, 10% FCS, 1% Ultroser G, at 37°C with
5% CO2.All experiments were carried out between P1
and P5 to avoid cell senescence. Myoblast purity was de-
termined by staining for Desmin. Purified myoblasts
were plated in collagen-coated Petri dishes and cultured
in growth medium containing DMEM supplemented
with 20% fetal bovine serum at 37°C in humidified at-
mosphere with 5% CO2. Myogenic differentiation of
confluent cells was induced after 5 days by changing to
DMEM containing 2% FBS (differentiation medium).
Cells were kept in differentiation medium for 3 days.
Myogenic fusion index at day three was 37-70%. Human
immortalized myoblasts (iMyo) (kind gift of Dr. V.
Mouly) were grown and differentiated as described in
[113]. RD and TE671 (a kind gift of Dr. S. Leibowitz)
were grown as described [114]. phrGFP-1 vector was
from Stratagen, pcDNA3.2/V5 hsa-mir-128 (#26308)
[115] and pCMV-miR30 (#20875) [116] vectors were pro-
vided by Addgene. Transient transfection of RD cells was
performed in 6-well plate format using Lipofectamine
2000 according to manufacturer’s instructions with minor
modification: 600.000 cells were added to the transfection
mixture prepared directly in the cell culture plate. To
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inhibitors of miR-1, -206, 133a and b, and the irrelevant
control were purchased from Exiqon (Denmark) and were
mixed with LipoRNAiMAX (Invitrogen) in 6-well plates
at 100nM final concentration, using 500 000 cells per well.
Reverse transcription and real-time PCR
For microRNA expression analysis 400 ng of total RNA
purified via Trizol (Invitrogen) was converted into cDNA
using 8 independent pools of primers (#4384791, Ap-
plied Biosystems, AB) and TaqMan microRNA Reverse
transcription kit (#4366596, AB). cDNA was quantified
using via qPCR using TaqMan 2x Universal PCR Master
Mix, No AmpErase UNG (#4324018, AB) and human
microRNA panel version 1.0 TLDA (TaqMan Low
Density Array, AB), data were acquired on AB7900HT
Real-Time PCR machine. Sequences of microRNAs and
corresponding codes of TaqMan assays can be found in
Additional file 2. For mRNA expression analysis total
RNA was isolated from 2x106 proliferating myoblasts, or
differentiated myotubes using Trizol (Invitrogen) and re-
verse transcribed using the High Capacity cDNA Arch-
ive kit (Applied Biosystems, AB) according to the
manufacturer protocol. cDNA was mixed with 2x
Taqman PCR mix (AB) and amplified customized TLDA
(TaqMan Low Density Array) using Abiprism 7900HT
apparatus (AB). In case of miRNA and mRNA the ex-
pression level was calculated from Ct values using ΔΔCt
method using GAPDH as a control [117]. The calcula-
tion of SEM in case of average of multiple samples has
been done as described in [118].
Transcriptome profiling and data processing
Human primary myoblasts were sacrificed directly on
plates at 30% confluency using Trizol, RNA was prepared
using organic extraction and ethanol precipitation as de-
scribed [119] followed by silica column cleanup on silica
columns (Nucleospin RNA Extraction kit, Macherey
Nagel). RNA extracted from individual myoblast lines was
Cy5-labeled, mixed with with a pool of RNA samples la-
beled with Cy3 and hybridized to Gene Expression
microarrays (4x44k #G4112F Agilent) and scanned as
instructed by the manufacturer. Scanned images were
then analysed using the Feature Extraction Software
(Agilent), the subsequent gene expression data treatment
was performed using R and Bioconductor. Spots with in-
tensity lower than 50 or lower than background in more
than 50% of biological replicates have been removed from
further analysis. The background correction and intensity
normalization procedures were applied for the re-
maining ~30 000 probes using the Bioconductor package
vsn [120]. A background offset and a scaling factor for
each array and dye channel were calculated using the least
squares regression procedure, then the generalized log-transformation was applied. The ordinary least squares re-
gression approach is based on the assumption that “most
genes are not differentially expressed”. However, in the
case of myogenic differentiation, where many genes are
differentially expressed, this assumption does not hold.
Therefore, to apply the above mentioned approach to
myogenic differentiation, the vsn least squares model has
first been applied to a subset of features, and then ex-
tended for the whole set of features. To select the sub-
set of features, a pool of samples prepared from five
different proliferating myoblast lines before and after
myogenic differentiation were hybridized to two add-
itional microarrays. Then 14.358 features that did not
exceed the cutoff value of 1.23 fold change between the
pools have been selected. To determine the differentially
expressed genes, a t-test analysis was conducted using the
limma package from Bioconductor [120]. Using this pack-
age, a linear model is fitted to the expression data for each
gene. An empirical Bayes moderation of the standard
errors were performed. This method borrows informa-
tion across genes in order to arrive at more stable esti-
mates of each individual gene’s variance, even for
experiments with small number of arrays. The microarray
data related to this paper have been submitted to the Array
Express data repository at the European Bioinformatics In-
stitute (http://www.ebi.ac.uk/arrayexpress) under the ac-
cession number E-MTAB-1577 (release date 2014-3-22).
miRNA targets predictions
RNA22 [40] and TargetScan algorithms [121] have been
used to predict miRNA target genes in this study. miRNA
targets identified by RNA22 have been downloaded from
the RNA22 website http://cbcsrv.watson.ibm.com/rna22.
html. Predictions were processed in the form of 30UTR
binding sites occurrence matrices, containing the number
of 30UTR binding sites for each combination of miRNA
(columns) and mRNA (rows).
Pearson correlation between mRNA and miRNA
expression profiles and permutation tests for significance
All the following has been performed using the R soft-
ware. Pearson correlation values were computed using
expression levels of each single transcript available and
for each miRNA, found to be differentially expressed
during myogenic differentiation in this study. Pearson
correlation values were retained for further analysis, if
they were corresponding to miRNA and mRNA pares
having at least one occurrence in at least one of the two
30UTR binding sites occurrence matrices. To distinguish
between biologically significant and random correlations,
we performed a permutation test. We performed nine
different permutations by calculating correlation values
using a miRNA table with permuted sample designa-
tions. Then, the distribution of the real and permuted
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percentile of the Pearson correlation obtained with the
permuted data was used as a threshold (th) for selecting
biologically significant target genes. For each differen-
tially expressed miRNA, the Pearson correlation value is
compared to th and if smaller, the gene is retained as a
biologically significant target gene regulated by the
miRNA, with a 5% risk of error.
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